IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10086043 B1

PDFFull Text
Date of Patent:
Oct. 02, 2018

Filed:

Mar. 12, 2012

Efficient protein expression in vivo using modified rna (mod-rna)

Applicants:

Kenneth R. Chien, Cambridge, MA (US);

Leon M. Ptaszek, Newton, MA (US);

Oi-lan Lui, Boston, MA (US);

Lior Zangi, Brookline, MA (US);

Wataru Ebina, Boston, MA (US);

Derrick J. Rossi, Roslindale, MA (US);

Inventors:

Kenneth R. Chien, Cambridge, MA (US);

Leon M. Ptaszek, Newton, MA (US);

Oi-Lan Lui, Boston, MA (US);

Lior Zangi, Brookline, MA (US);

Wataru Ebina, Boston, MA (US);

Derrick J. Rossi, Roslindale, MA (US);

Assignees:

THE GENERAL HOSPITAL CORPORATION, Boston, MA (US);

CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US);

Attorney:

Nixon Peabody LLP

Primary Examiner:

Christopher M Babic

Assistant Examiner:

Kimberly A Aron

Int. Cl.
CPC ...
A61K 38/18 (2006.01); A01K 67/027 (2006.01); A61K 48/00 (2006.01); C12N 15/11 (2006.01); A61K 31/7115 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1866 (2013.01); A01K 67/0276 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 31/7115 (2013.01); A61K 33/24 (2013.01); A61K 48/005 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C12N 15/111 (2013.01); A01K 2207/05 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0393 (2013.01); A61L 2300/258 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2800/30 (2013.01);
Abstract

Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.

Find Patent Forward Citations

Loading…